Watchlist Price Alert

Phathom Pharmaceuticals I... (PHAT)

NASDAQ: PHAT · Real-Time Price · USD

4.31

0.23 (5.64%)

At close: May 29, 2025, 3:59 PM

4.26

-1.16%

After-hours: May 29, 2025, 05:49 PM EDT

5.64% (1D)

Bid	4
Market Cap	300.9M
Revenue (ttm)	81.86M
Net Income (ttm)	-251.47M
EPS (ttm)	-5.18
PE Ratio (ttm)	-0.83
Forward PE	-12.7
Analyst	Buy

Ask	4.48
Volume	732,495
Avg. Volume (20D)	1,684,204
Open	4.15
Previous Close	4.08
Day's Range	4.06 - 4.34
52-Week Range	2.21 - 19.71
Beta	0.15

About PHAT

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol PHAT

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for PHAT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

3 weeks ago

-17.86%

Phathom Pharmaceuticals shares are trading lower a... Unlock content with Pro Subscription

4 weeks ago

-21.68%

Phathom Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q1 EPS and Sales results.

News

3 weeks ago · zacks.com

After Plunging -45.82% in 4 Weeks, Here's Why the Trend Might Reverse for Phathom Pharmaceuticals (PHAT)

Phathom Pharmaceuticals (PHAT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analys...

4 weeks ago · seekingalpha.com

Phathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call Transcript

4 weeks ago · zacks.com

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates

Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $1.07 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to loss of $1.42 per share a year ago.

1 month ago · businesswire.com

Frazier Life Sciences Appoints Aditya Kohli to Partner

PALO ALTO, Calif.--(BUSINESS WIRE)--Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Aditya Kohli, Ph.D., to Partner. ...

2 months ago · seekingalpha.com

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2024 Earnings Call Transcript

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants Eric Sciorilli - Head, Investor Relations Terrie Curran - President & Chief ...

2 months ago · zacks.com

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Tops Revenue Estimates

Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to loss of $0.80 per share a year ago.